Newron Pharmaceuticals has secured up to €38mn to advance Phase III trials of evenamide, a drug that, if successful, could represent one of the first circuit-modulating therapies in schizophrenia.
Tag Archive for: Schizophrenia
Nxtera Pharma LtdNxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.